Cortical's board of management has welcomed Dr Su-Peing Ng who joined the company as CEO on 19 August 2004.Dr Ng joins Cortical having recently returned from the UK where she was Business Development Director for Chiron Vaccines responsible for the company's US$300m influenza franchise.
Cortical's core strengths are medicinal chemistry, applied biology and virtual drug development.Dr Ng
brings to the company several years of international pharmaceutical and biotechnology business and commercial strategy development experience.Dr Ng is a qualified medical practitioner and holds an MBA from the Melbourne Business School where she graduated with distinction.
As part of her
MBA program, Dr Ng
studied at the Fuqua Business School at Duke University
Dr Ng's mission for Cortical
is to expand the pipeline beyond the current focus of macrophage migratory inhibitory factor (MIF) to include other molecules with potential anti-inflammatory effects.In early October (6th - 7th), Dr Ng
will participate in an Australian Biotechnology Mission to the Medicon Valley conference at Bella Center
"As a niche Australian biotechnology company, the mission provides an ideal opportunity to showcase our research and development activities and to meet other prospective research and commercialisation partners.I am very pleased to be part of this initiative," said Dr Ng
For further information, or to arrange an interview with Dr Su-Peing Ng
, please contact Katrina Weir on (02) 9436 2088 or email email@example.com.